# EDGAR Filing Document

**Accession Number:** 0001826397
**File Stem:** 0001493152-26-005802
**Filing Date:** 2026-2
**Character Count:** 94207
**Document Hash:** fd8e594ee8c8d36f0bc8f1e0b34e3f06
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-005802.hdr.sgml**: 20260209

**ACCESSION NUMBER**: 0001493152-26-005802

**CONFORMED SUBMISSION TYPE**: S-3

**PUBLIC DOCUMENT COUNT**: 13

**FILED AS OF DATE**: 20260209

**DATE AS OF CHANGE**: 20260209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVAX ONE TECHNOLOGY LTD.
- **CENTRAL INDEX KEY:** 0001826397
- **STANDARD INDUSTRIAL CLASSIFICATION:** FINANCE SERVICES [6199]
- **ORGANIZATION NAME:** 09 Crypto Assets
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-3
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293312
- **FILM NUMBER:** 26612216

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 800-525 WEST 8TH AVENUE
- **CITY:** VANCOUVER
- **PROVINCE COUNTRY:** A1
- **BUSINESS PHONE:** 1-866-226-3514

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 800-525 WEST 8TH AVENUE
- **CITY:** VANCOUVER
- **PROVINCE COUNTRY:** A1

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AGRIFORCE GROWING SYSTEMS LTD.
- **DATE OF NAME CHANGE:** 20200928

**AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON FEBRUARY 9, 2026**

**REGISTRATION NO. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-3**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**AVAX ONE TECHNOLOGY LTD.**

(Exact name of registrant as specified in its charter)

<u>British Columbia</u>

(State or other jurisdiction of incorporation or organization)

Not applicable.

I.R.S. Employer Identification Number

---

| | |
|:---|:---|
| **800-525 West 8th Avenue**<br> **Vancouver, BC, Canada V5Y 1C6** | **V5Y 0M6** |
| (Address of principal executive offices) | (Zip Code) |

---

**(604) 757-0952**

(Telephone Number)

**Jolie Kahn, Esq.**

**430 Park Avenue, 19th floor**

**New York, NY 10022**

**(516) 217-6379**

*(Address, including zip code, and telephone number,*

*including area code, of agent for service)*

Copies to:

Jolie Kahn, Esq.

430 Park Avenue, 19th floor

New York, NY 10022

Phone: (516) 217-6379

Fax: (866) 705-3071

Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission (the "Commission"), acting pursuant to said Section 8(a), may determine.**

**The information in this prospectus is not complete and may be changed. We may not sell these securities or accept your offer to buy any of them until the registration statement filed with the Securities and Exchange Commission is declared effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.**

---

| | | |
|:---|:---|:---|
| **PRELIMINARY PROSPECTUS** | **SUBJECT TO COMPLETION** | **DATED FEBRUARY 9, 2026** |

---

**AVAX ONE TECHNOLOGY LTD.**

**Up to 4,792,533 Common Shares**

Pursuant to this prospectus, the selling shareholders of AVAX One Technology Ltd., a British Columbia corporation (the "Company"), identified in this prospectus (the "selling shareholders") may offer common shares, without par value ("common shares"), from time to time if and to the extent as such selling shareholders may determine, as described in the section entitled "Plan of Distribution," at prevailing market prices, at prices based upon prevailing market prices or at negotiated prices. If any common shares are sold, the selling shareholders will pay any brokerage commissions and/or similar charges incurred for the sale of such shares.

We are filing the prospectus to permit the resale of up to 4,792,533 common shares issuable upon conversion of notes and exercise of warrants issued in a January 2, 2026 additional tranche of $7,000,000 with a 10% original issue discount for gross proceeds of $6,300,000. The convertible debt and warrants were issued with an exercise and strike price of $2.41.

We are not selling any common shares included in this prospectus. While we will not receive any of the proceeds from the sale of any common shares sold by the selling shareholders pursuant to this prospectus, we will receive proceeds from any exercise of the selling shareholder warrants, assuming such exercise does not occur on a cashless exercise basis. See the additional information provided under the headings "Use of Proceeds" and "Selling Shareholders."

The Company's headquarters is located at 800-525 West 8th Avenue, Vancouver, BC, Canada V5Z 1C6, and our telephone number is (604) 757-0952.

Our common shares are listed and posted for trading on the Nasdaq Capital Market ("Nasdaq") under the symbol "AVX." On February 6, 2026, the closing price of our common shares on Nasdaq was $0.6611 per common share.

We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus, including the additional information described under the heading "Incorporation of Certain Information by Reference," and any amendments or supplements carefully before you make your investment decision.

**Investing in our securities involves a high degree of risk. Before buying our securities, you should consider carefully the risks described under the caption "Risk Factors" beginning on page 9 of this prospectus and in the documents incorporated by reference in this prospectus and refer to the risk factors that may be included in a prospectus supplement and in our reports and other information that we file with the U.S. Securities and Exchange Commission (the "SEC").**

**Neither the SEC nor any state or Canadian securities commission or regulator has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

This prospectus is dated ________ __, 2026.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | Page |
| [ABOUT THIS PROSPECTUS](#sa_001) | 1 |
| [SUMMARY](#sa_002) | 1 |
| [RISK FACTORS](#c_001) | 9 |
| [CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS](#c_002) | 11 |
| [USE OF PROCEEDS](#c_003) | 12 |
| [DESCRIPTION OF COMMON SHARES](#c_004) | 13 |
| [SELLING SHAREHOLDERS](#c_005) | 14 |
| [PLAN OF DISTRIBUTION](#c_006) | 15 |
| [LEGAL MATTERS](#c_007) | 16 |
| [EXPERTS](#c_008) | 16 |
| [WHERE YOU CAN FIND MORE INFORMATION](#c_009) | 16 |
| [INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE](#c_010) | 17 |

---

I

**ABOUT THIS PROSPECTUS**

This prospectus is a part of a registration statement that we filed with the U.S. Securities and Exchange Commission (the "SEC"), using a "shelf" registration process. Under this shelf registration statement, we or selling securityholders may offer and sell common shares and preferred shares and various series of warrants to purchase common shares or preferred shares, in each case, individually or in units, from time to time and in one or more offerings up to a total dollar amount of $2,000,000,000. Any of the securities described in this prospectus and in a prospectus supplement may be convertible into or exercisable or exchangeable for other securities that are described in this prospectus or which will be described in a prospectus supplement. These securities may include new or hybrid securities developed in the future that combine features of any of the securities described in this prospectus.

As allowed by SEC rules, this prospectus provides you with a general description of the securities we may offer, which is not meant to be a complete description of each of the securities. Each time we offer and sell securities, we will provide one or more prospectus supplements that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you in connection with an offering. Any prospectus supplement or free writing prospectus may also add, update, or change information contained in this prospectus. We urge you to carefully read this prospectus, any applicable prospectus supplement and any related free writing prospectuses prepared by or on behalf of us or selling securityholders or to which we have referred you, together with the information incorporated by reference as described under the headings "Where You Can find Additional Information" and "Incorporation of Certain Information by Reference," including the risks referred to under the heading "Risk Factors" in this prospectus, in the applicable prospectus supplement and any related free writing prospectus and in the other documents that are incorporated by reference into this prospectus, before buying any of the securities being offered. Statements contained in this prospectus and any accompanying prospectus supplement or in any applicable free writing prospectus about the provisions or contents of any agreement or other document are not necessarily complete. If the SEC's rules and regulations require that an agreement or document be filed as an exhibit to the registration statement, please see that agreement or document for a complete description of these matters.

**You should rely only on the information incorporated by reference or provided in this prospectus, any accompanying prospectus supplement or any applicable free writing prospectuses prepared by or on behalf of us or to which we have referred you. We have not authorized anyone else to provide you with any other information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted.**

**THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.**

Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by us or on our behalf or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor does this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.

You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the applicable document. You should also not assume that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date.

This prospectus and the information incorporated by reference in this prospectus contain summaries of provisions of certain other documents, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to in this prospectus have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading "Where You Can Find More Information."

**You should only rely on the information contained or incorporated by reference in this prospectus, any prospectus supplement or any related free writing prospectus. We have not authorized anyone to provide you with information different from what is contained or incorporated by reference into this prospectus, applicable prospectus supplement or any related free writing prospectus. If any person does provide you with information that differs from what is contained or incorporated by reference in this prospectus, applicable prospectus supplement or any related free writing prospectus, you should not rely on it. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, applicable prospectus supplement or any related free writing prospectus. You should assume that the information contained in this prospectus, any prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document and that any information contained in any document we have incorporated by reference therein is accurate only as of the date on its face, regardless of the time of delivery of this prospectus, any prospectus supplement, any related free writing prospectus or any sale of a security under this registration statement. These documents are not an offer to sell or a solicitation of an offer to buy these securities in any circumstances under which the offer or solicitation is unlawful.**

**SUMMARY**

This summary highlights selected information from this prospectus and does not contain all of the information that you should consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading "Risk Factors" contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a component.

The terms "AVAX One," the "Company," "we," "our" or "us" in this prospectus refer to AVAX One Technology Ltd. and its wholly-owned subsidiaries, unless the context suggests otherwise.

**About the Company**

***General***

The Company was incorporated as a private company by Articles of Incorporation issued pursuant to the provisions of the *Business Corporations Act (British Columbia)* on December 22, 2017. The Company's registered and records office address is at 800 – 525 West 8<sup>th</sup> Avenue, Vancouver, British Columbia, Canada, V5Z 1C6, and our telephone number is (604) 757-0952.

***Business Overview***

AVAX One Technology Ltd., formerly known as AgriFORCE Growing Systems Ltd., ("AVAX One" or the "Company") was incorporated on December 22, 2017 as a private company by filing of Articles of Incorporation in the Province of British Columbia pursuant to the provisions of the *Business Corporations Act (British Columbia)*. The Company's registered and records office address is at 800 – 525 West 8<sup>th</sup> Avenue, Vancouver, British Columbia, Canada, V5Z 1C6. On November 13, 2025, the Company changed its name to AVAX One Technology Ltd. (the defined term the "Company" also includes the recent name change entity to AVAX One Technology Ltd.) and its Nasdaq ticker symbol to AVX.

*Transition to AVAX One*

On September 22, 2025, the Company entered into subscription agreements (each, a "Subscription Agreement" and collectively, the "Subscription Agreements") with certain institutional and accredited investors (each, an "Investor" and collectively, the "Investors"), pursuant to which the Company, subject to the restrictions and upon satisfaction of the conditions in the Subscription Agreements, agreed to sell in one or more private placement transactions exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Offering"), to the Investors Company common shares, no par value per share (in generality, the "Common Shares", and the aggregate number thereof referenced in this sentence, the "Shares"). The per Share purchase price was $2.36 (the "Share Price").

On November 5, 2025 (the "Closing Date"), upon the satisfaction of all conditions in the Subscription Agreements, the PIPE Transaction closed, and the Company issued to the Investors an aggregate of 86,690,657 Common Shares and pre-funded warrants (the "Pre-Funded Warrants") exercisable for an aggregate of 6,123,837 Common Shares in the PIPE Transaction. The Common Shares were sold at an offering price of $2.36 per Common Share, and the Pre-Funded Warrants were sold at an offering price of $2.3599 per Pre-Funded Warrant, which represents the per share offering price less the $0.0001 per share exercise price for each such Pre-Funded Warrant.

The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

Of the aggregate $219.0 million purchase price for the Shares, an aggregate of (i) $145.4 million was paid in cash, the cryptocurrency stablecoin commonly referred to as USDC ("USDC") based on a purchase price of $1.00 per USDC, and the cryptocurrency stablecoin commonly referred to as USDT ("USDT" and together with USDC, "Stablecoins") based on a purchase price of $1.00 per USDT, and (ii) $73.7 million was paid in the native cryptocurrency of the Avalanche Network, referred to as AVAX Tokens ("AVAX Tokens"), which was valued for purposes of the Subscription Agreements at the volume-weighted average price of an AVAX Token (rounded to two decimal places) during the 14 consecutive calendar days ending on the Funding Payment Deadline (as defined in the Subscription Agreements) based on midnight UTC, calculated by using the hourly volume and the Messari Price as reported on messari.io (the "Specified AVAX Token Value").

As of the Closing Date and after giving effect to the Common Shares (but not pre funded warrants) issued in the PIPE transaction, there were 93,112,148 Common Shares issued and outstanding.

Cohen & Company Securities, LLC acted as the sole placement agent in connection with the Offering.

The Company intends to use up to $10 million of the cash net proceeds from the Offering for general corporate purposes initiated after closing and for pre-existing working capital commitments or obligations, and the remaining cash net proceeds for the acquisition of AVAX Tokens. The AVAX Tokens acquired, together with the remaining net proceeds, will be used for the establishment of the Company's cryptocurrency treasury operations to the extent consistent with the Company's investment policy as amended or otherwise modified from time to time. In connection with the announcement of the Offering, the Company announced the launch of its digital asset treasury reserve strategy, which became effective upon the closing of the Offering, pursuant to which the Company plans to use AVAX Tokens as its primary treasury reserve asset on an ongoing basis.

The Company also intends to continue substantive operation of its Bitcoin mining business. The Company's current management team, consisting of Jolie Kahn, as Chief Executive Officer, and Chris Polimeni, as Chief Financial Officer, will continue in their respective roles with the Company after the closing of the Offering. Furthermore, with the exception of Amy Griffith who is continuing as a director of the Company after closing, all prior directors of the Company resigned on the Closing Date of the Offering and were replaced by the newly appointed directors.

*Registration Rights*

In the Subscription Agreements, the Company agreed to, among other things, use reasonable best efforts to submit or file with the Securities and Exchange Commission (the "SEC"), within 30 calendar days after the closing of the Offering, a registration statement on Form S-3 (or Form S-1 if Form S-3 is not available) (the "Registration Statement"), registering the resale of the Registrable Securities (as defined below), and the Company agreed to use its commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable after filing and upon the earlier of (i) the twenty-fifth (25<sup>th</sup>) business day (or sixtieth (60<sup>th</sup>) business day if the SEC notifies the Company that it will "review" the Registration Statement) following the filing date and (ii) the 5th business day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the Registration Statement will not be "reviewed" or will not be subject to further review. The Company agreed to use commercially reasonable efforts to maintain the effectiveness of the Registration Statement until the earlier of (a) the Investors cease to hold any Registrable Securities, (b) the date all Registrable Securities held by the Investors may be sold without restriction under Rule 144 of the Securities Act, including without any volume and manner of sale restrictions which may be applicable to affiliates under Rule 144 and without the requirement for the Issuer to be in compliance with the current public information required under Rule 144, and (c) three years from the effective date of the Registration Statement. "Registrable Securities" means the Shares and any Common Shares issued or issuable with respect to the Shares as a result of any share split or subdivision, share dividend, recapitalization, exchange or similar event.

*Asset Management Agreement*

On September 18, 2025, the Company entered into an Asset Management Agreement (the "Asset Management Agreement") with Hivemind Capital Partners, LLC (the "Asset Manager"). The Asset Manager shall provide discretionary asset management services with respect to, among other assets (including without limitation certain subsequently raised, received or allocated funds or assets), the Company's proceeds from the Offering (the "Account Assets") in connection with any of the Company's digital asset strategies, in accordance with the terms of the Asset Management Agreement. The custodians under the Asset Management Agreement will consist of cryptocurrency wallet providers agreed to by the Company and the Asset Manager. The Asset Management Agreement will become effective upon closing of the Offering.

The Company shall pay the Asset Manager an annual management fee (the "Management Fee") equal to one and one-quarter percent (1.25%) of the Account Size (as defined in the Asset Management Agreement). The Management Fee will be calculated and payable quarterly in advance, as of the first business day of each calendar quarter. In addition to the Management Fee, the Company will reimburse the Asset Manager for all documented out-of-pocket expenses incurred by the Asset Manager in connection with the performance of the Asset Manager's duties under the Asset Management Agreement.

The Asset Management Agreement will, unless early terminated, continue in effect until the tenth anniversary of the Effective Date (as defined in the Asset Management Agreement) and, unless a party to the agreement elects to not continue the effectiveness of the Asset Management Agreement, will continue for successive five-year renewal periods upon the mutual agreement of the Asset Manager and the Company. The Asset Management Agreement may be terminated at any time for cause (i) by the Company upon at least 30 days prior written notice to the Asset Manager and (ii) by the Asset Manager upon at least 60 days prior written notice to the Company. The Asset Manager may immediately terminate the Asset Management Agreement upon written notice to the Company if the Asset Manager reasonably determines that the continuation of its services or the Asset Management Agreement would result in a violation of any applicable law, regulation, or regulatory guidance.

*Strategic Advisor Agreement*

On the Closing Date, in connection with the closing of the PIPE Transaction, the Company entered into two Strategic Advisor Agreements (each, a "Strategic Advisor Agreement" and collectively, the "Strategic Advisor Agreements") with each of Anthony Scaramucci (through Ground Tunnel Capital LLC) and Brett Tejpaul (Messrs. Scaramucci and Tejpaul are collectively referred to as the "Strategic Advisors"), pursuant to which the Company engaged the Strategic Advisors to provide strategic advice and guidance relating to the Company's business, operations, growth initiatives and industry trends in the digital asset and financial services sector for an initial term of one year, which will automatically renew for up to two successive one year periods unless the respective Strategic Advisor or the Company provides written notice of its intention not to extend. Either the Company or the Strategic Advisor may terminate a Strategic Advisor Agreement upon 30 days' prior written notice to the other party in the event of a material breach that remains uncured at the end of such 30-day period or immediately upon written notice to the other party in the event of willful misconduct, gross negligence, or fraud by such other party or any allegation thereof.

Pursuant to the terms of each Strategic Advisor Agreement, the Company issued to the Strategic Advisors an aggregate of 928,145 restricted Common Shares (the "Strategic Advisor Shares"). These Shares vest monthly over a period of 36 months in equal increments in the aggregate of 1/36 of the total Strategic Advisor Shares per month, and if the Agreements are terminated at the end of any one year period, any unvested shares will be forfeited. The Strategic Advisor Agreements also contain customary representations and warranties, confidentiality provisions and limitations on liability.

On September 17, 2025, the Company's Board of Directors approved the issuance of restricted Common Shares to the following parties in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, which shares shall be issued on September 18, 2025 at a price equal to the per share closing price on September 17, 2025. All shares issued hereunder are subject to lockup agreements entered into by those officers and directors in January 2025.

Each of directors, David Welch, John Meekison, Elaine Goldwater and Richard Levychin, received 42,194 restricted common shares, and director, Amy Griffith received 21,097 restricted common shares.

Jolie Kahn received 46,413 restricted common shares owed to her for compensation due for prior services rendered.

Each of Jolie Kahn and Chris Polimeni received an equity bonus of 105,485 restricted common shares in recognition of prior services to the Company.

David Welch received 42,194 restricted common shares in recognition of prior services to the Company.

On September 15, 2025 and September 17, 2025, Company common shares were issued to the following parties in partial conversion of the Debentures previously issued to them by the Company in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.

---

| | | |
|:---|:---|:---|
| 09/15/25 | Pioneer Capital Anstalt | 156155.0 |
| 09/17/25 | Anson Investments Master Fund | 193440.0 |
| 09/17/25 | Anson East Master Fund LP | 54560.0 |

---

 

On November 19, 2025, the Company's Board of Directors (the "Board") has authorized a share repurchase program of up to $40 million of the Company's common shares. The Board will periodically review the Company's Repurchase Program and may decide to extend its term or increase the authorized amount. Repurchases under the program, which has a one year term, may be made from time to time through open market purchases or other means permitted under applicable securities laws and regulations. The timing and amount of repurchases under the program will depend on market conditions, regulatory requirements, capital allocation alternatives, and other corporate considerations. The Company is not obligated to repurchase any specific number of shares, and the program may be suspended or discontinued at any time.

As of November 12, 2025, the Company purchased in the ordinary course of business 7,220,216.61 AVAX tokens from the Avalanche Foundation for a total purchase price of $80,000,000.

*Reverse Share Split*

On July 28, 2025, the Company effected a one-for-nine reverse share split of the Company's issued and outstanding common shares (the "Reverse Split"). As a result of the Reverse Split, every 9 shares of the Company's old common shares were converted into one share of the Company's new common shares. Fractional shares resulting from the Reverse Split were sold at the then prevailing price on the open market, with the proceeds being distributed on a pro-rata basis to the impacted shareholders. The Reverse Split automatically and proportionately adjusted all issued and outstanding shares of the Company's common shares, as well as convertible debentures, convertible features, prefunded warrants, options and warrants outstanding at the time of the date of the Reverse Split. The exercise price on outstanding equity-based grants was proportionately increased, while the number of shares available under the Company's equity-based plans was proportionately reduced. Share and per share data (except par value) for the periods presented reflect the effects of the Reverse Split. References to numbers of common shares and per share data in the accompanying financial statements and notes thereto for periods ended prior to July 28, 2025 have been adjusted to reflect the Reverse Split on a retroactive basis.

**Executive Compensation**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| Name & Principal Position | Year | Salary | Bonus | Share-Based Awards | Option-Based Awards | All Other | Total Compensation |
| Jolie Kahn | 2025 | 370083 | – | 540822 | – |  | 910905 |
| &nbsp;&nbsp;&nbsp;Chief Executive Officer | 2024 | 312611 | – | 25000 | – |  | 337611 |
| Chris Polimeni | 2025 | 220000 | – | 250000 | – |  | 470000 |
| &nbsp;&nbsp;&nbsp;Chief Financial Officer | 2024 |  | – |  | – |  |  |
| Peter Wylie | 2025 | 70000 | – | 150000 | – |  | 220000 |
| &nbsp;&nbsp;&nbsp;Chief Operating Officer | 2024 |  | – |  | – |  |  |
| Richard S. Wong (a) | 2025 | 251734 | – | 100609 | – | 127477 | 479821 |
| &nbsp;&nbsp;&nbsp;Former Chief Financial Officer | 2024 | 260166 | – | 41066 | – | 1793 | 303025 |
| Mauro Pennella (a) | 2025 | 215672 | – | 164374 | – | 187795 | 567842 |
| &nbsp;&nbsp;&nbsp;Former Chief Marketing Officer | 2024 | 255512 | – | 54753 | – | 1793 | 312058 |

---

(a) Some
 share-based awards were issued net of income taxes. The Company repurchased shares on the issuance date to remit as income taxes
 to the appropriate government revenue service agencies.

**Director Compensation**

Under our independent, non-employee director compensation program, each non-employee, independent director receives cash compensation of $75,000 per annum and an annual grant of restricted shares of common stock equal to $75,000. The restricted shares vest on a quarterly basis. In addition, if the director serves on a committee of our Board, the director will receive additional annual cash fees of $20,000 for each committee the director is a member of.

Cash director fees are payable in arrears in quarterly installments not later than the fifteenth day following the final day of each calendar quarter and prorated for any portion of a quarter that a director is not serving as an independent, non-employee director or a committee member on our Board. Directors are also reimbursed for reasonable expenses associated with attending Board and committee meetings.

In addition to director fees discussed above, we provide equity incentive compensation to our directors in order to align their interests with those of our stockholders. Equity incentive awards for directors are granted pursuant to the terms of the 2019 Option Plan and 2024 Equity Incentive Plan. Awards for our directors have been granted in the form of RSUs rather than stock options, which is consistent with the grant type used for our executive officers. Directors do not typically receive an onboarding grant at the time of appointment, and are instead eligible to receive annual grants as determined in the discretion of the committee.

***2025 Director Compensation Table***

The following table sets forth all compensation paid or awarded to our non-employee directors for service to us during 2025. The amounts set forth in the table have been calculated in accordance with the requirements of applicable SEC rules, and do not necessarily reflect the amounts that have actually been paid to, or which may be realized by, our directors.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Year** | **Fees Earned or** **Paid in Cash**<br> **($)** | **RSU Awards**<br> **($)** | **All Share-based compensation**<br> **($)** | **Total**<br> **($)** |
| **Matt Zhang** | 2025 |  | – |  |  |
| **Xiao-Xiao Jiehua Zhu** | 2025 | 17500 | – | 75000 | 92500 |
| **Young Chi Cho** | 2025 | 17500 | – | 75000 | 92500 |
| **Daniel Mendes** | 2025 | 17500 | – | 75000 | 92500 |
| **Amy Griffith** | 2025 | 137292 | – | 125000 | 262292 |
| **David Welch (former Chairman)** | 2025 | 161458 | – | 350000 | 511458 |
| **William J. Meekison(former director)** | 2025 | 88542 | – | 100000 | 188542 |
| **Richard Levychin (former director)** | 2025 | 88542 | – | 100000 | 188542 |
| **Elaine Goldwater (former director)** | 2025 | 114583 | – | 100000 | 214583 |

---

***Equity Awards Held by Directors***

There were no RSUs held as of December 31, 2025 by any of our non-employee directors who was serving as of December 31, 2024. All RSUs granted to our non-employee directors are immediately vested and settled on the grant date. We have not issued stock options or any other type of equity awards to our non-employee directors.

Please refer to the section of this Proxy Statement titled "*Security Ownership of Certain Beneficial Owners and Management*" for additional information about the beneficial ownership of our securities by our executive officers and directors.

**Equity Compensation Plan Information**

The following table provides information with respect to options outstanding under our Plan as at December 31, 2025:

---

| | | | |
|:---|:---|:---|:---|
| **Plan category** | **Number of**<br> **securities to**<br> **be issued**<br> **upon exercise of**<br> **outstanding options** | **Weighted-average**<br> **exercise price of**<br> **outstanding options** | **Number of**<br> **securities**<br> **remaining**<br> **available for**<br> **future issuance** |
| Equity compensation plans approved by security holders |  | $- | 13940820 |
| Equity compensation plans not approved by security holders |  | - | - |
| **Total** |  | $- | 13940820 |

---

**Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters**

The following table sets forth information known to us regarding the beneficial ownership of our common stock as of February 2, 2026 by:

● each
 person known to us to be the beneficial owner of more than 5% of our outstanding common stock;

● each
 of our executive officers and directors; and

● all
 of our executive officers and directors as a group.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common**<br> **shares** | **Options**<br> **Granted vested**<br> **within 60 days of**<br> **Feb 2, 2026** | **Warrants** | **Total** | **Percentage**<br> **beneficially**<br> **owned** |
| **Directors and Officers:** |  |  |  |  |  |
| Jolie Kahn | 167737 |  |  | 167737 | 0.18% |
| Chris Polimeni | 105485 |  |  | 105485 | 0.11% |
| Peter Wylie | 61224 |  |  | 61224 | 0.07% |
| Matt Zhang |  |  |  |  | 0.00% |
| Xiao-Xiao Jiehua Zhu | 30612 |  |  | 30612 | 0.03% |
| Young Chi Cho |  |  |  |  | 0.03% |
| Daniel Mendes | 30612 |  |  | 30612 | 0.03% |
| Amy Griffith | 51709 |  |  | 51709 | 0.06% |
| Total all officers and directors (8 persons) | 477991 |  |  | 167737 | 0.51% |
| **5% or Greater Beneficial Owners** |  |  |  |  |  |

---

**Certain Relationships and Related Transactions, and Director Independence**

We have adopted a written related-person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight of "related-party transactions." For purposes of our policy only, and not for purposes of required disclosure, which will be all related party transactions, even if less than $120,000, a "related-party transaction" is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any "related party" are participants involving an amount that exceeds $120,000.

Transactions involving compensation for services provided to us as an employee, consultant or director are not considered related-person transactions under this policy. A related party is any executive officer, director or a holder of more than five percent of our common shares, including any of their immediate family members and any entity owned or controlled by such persons.

At present, we have appointed independent directors to the N&CG Committee. As a result, our Chief Financial Officer, Chris Polimeni, must present information regarding a proposed related-party transaction to the Nominating and Corporate Governance Committee. Under the policy, where a transaction has been identified as a related-party transaction, Mr. Polimeni must present information regarding the proposed related-party transaction to our Nominating and Corporate Governance Committee, once the same is established, for review. The presentation must include a description of, among other things, the material facts, the direct and indirect interests of the related parties, the benefits of the transaction to us and whether any alternative transactions are available. To identify related-party transactions in advance, we rely on information supplied by our executive officers, directors and certain significant shareholders. In considering related-party transactions, our Nominating and Corporate Governance Committee takes into account the relevant available facts and circumstances including, but not limited to:

● whether the transaction was undertaken in the ordinary course of our business;

● whether the related party transaction was initiated by us or the related party;

● whether the transaction with the related party is proposed to be, or was, entered into on terms no less favorable to us than terms that could have been reached with an unrelated third party;

● the purpose of, and the potential benefits to us from the related party transaction;

● the approximate dollar value of the amount involved in the related party transaction, particularly as it relates to the related party;

● the related party's interest in the related party transaction, and

● any other information regarding the related party transaction or the related party that would be material to investors in light of the circumstances of the particular transaction.

The Nominating and Corporate Governance Committee shall then make a recommendation to the Board, which will determine whether or not to approve of the related party transaction, and if so, upon what terms and conditions. In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval.

Except as set forth below, we have not had any related party transactions, regardless of dollar amount:

As of December 31, 2025, $17,500 (December 31, 2024 - $600,000) in total was owing to officers and directors or to companies owned by officers and directors of the Company for services and expenses. These amounts owing have been included in accounts payable and accrued liabilities.

During the year ended December 31, 2025 and 2024, the Company incurred $17,946 and $51,588, respectively, to our U.S. general counsel firm, Enso Law against legal services, a corporation controlled by a former director of the Company. As of December 31, 2025, $nil (December 31, 2024 - $5,647) in total was owed to Enso Law.

During the year ended December 31, 2024, the Company incurred $67,500 of legal fees to Jolie Kahn, who is also the CEO of the Company. As of December 31, 2025, $nil (December 31, 2024, $49,151) in total was owed to Jolie Kahn.

**Principal Accounting Fees and Services**

Aggregate fees billed to us by CBIZ CPAs P.C. and Marcum LLP, the Company's principal independent accountants, during the last two fiscal years were as follows:

---

| | | |
|:---|:---|:---|
|  | **December 31, 2025** | **December 31, 2024** |
| Audit Fees<sup>a</sup> | $594602 | $242308 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(a) Amounts
 represent the contractual fees related to the fiscal year, not the accrued fees incurred during the year.

Audit Fees consist of fees billed for professional services rendered for the audit of our consolidated annual financial statements and review of the interim consolidated financial statements included in quarterly reports, S-1 filings, comfort letters, and services that are normally provided by our auditors in connection with statutory and regulatory filings or engagements.

During the years ended December 31, 2025 and 2024, CBIZ CPAs P.C. did not incur fees for any other professional services.

**RISK FACTORS**

Investing in any securities offered pursuant to this prospectus, the applicable prospectus supplement and any related free writing prospectus involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described under "*Risk Factors*" in the applicable prospectus supplement, any related free writing prospectus and in our most recent Annual Report on Form 10-K, or any updates in our Quarterly Reports on Form 10-Q, together with all of the other information appearing in or incorporated by reference into this prospectus, the applicable prospectus supplement, which may include additional risk factors, and any related free writing prospectus, before deciding whether to purchase any of the securities being offered. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.

***Declines in the broader cryptocurrency market could adversely affect the AVAX token, our business and the value of our digital assets.***

The market prices of cryptocurrencies, including AVAX tokens and any others that we may hold or use in connection with our products and services, have historically been subject to extreme volatility. Broad declines in cryptocurrency values — whether due to regulatory developments, macroeconomic conditions, reduced adoption, security breaches, market manipulation, or other factors — could materially and adversely affect demand for our offerings, our financial condition, and the fair value of any digital assets we hold. Sustained or significant downturns in the cryptocurrency market could reduce customer activity, impair our ability to raise capital, and lead to write-downs or other non-cash charges, any of which could negatively impact our business and operating results and the trading price of our common shares.

***In relation to our acquisition, accumulation, holding, storing, selling, transferring or otherwise using any cryptocurrencies, there is a risk that rules or regulations could change, impacting the value of any such cryptocurrencies we hold and our ability to continue to use them or how we recognize, use and value them.***

As cryptocurrencies are relatively novel and the application of state and federal securities laws and other laws and regulations to cryptocurrencies are unclear in certain respects, it is possible that regulators in the United States or foreign countries may interpret or apply existing laws and regulations in a manner that adversely affects the price of cryptocurrencies. The U.S. federal government, states, regulatory agencies, and foreign countries may also enact new laws and regulations, or pursue regulatory, legislative, enforcement or judicial actions, that could materially impact the price of cryptocurrencies or the ability of individuals or institutions such as us to own or transfer cryptocurrencies.

If cryptocurrencies are determined to constitute a security for purposes of the federal securities laws, the additional regulatory restrictions imposed by such a determination could adversely affect the market price of cryptocurrencies and in turn adversely affect the market price of our common stock. Moreover, the risks of us engaging in a cryptocurrency treasury strategy have created, and could continue to create complications due to the lack of experience that third parties have with companies engaging in such a strategy, such as increased costs of director and officer liability insurance or the potential inability to obtain such coverage on acceptable terms in the future. Additional risks include, but are not limited to, changes in how we must value any cryptocurrencies we hold, which could impact our balance sheet and income statement, or our ability to hold, use or dispose of them. In addition, new forms of taxation on the receipt, accumulation, acquisition, holding, storing, transferring, selling or otherwise using cryptocurrencies could alter, diminish or destroy the value proposition for such cryptocurrencies or how we value any cryptocurrencies we may hold at that time, which could negatively impact our balance sheet or income statement.

***A principal component of our cryptocurrency treasury reserve policy is the acquisition of AVAX tokens, the price of which has been, and will likely continue to be, highly volatile. Our operating results and share price may significantly fluctuate due to the highly-volatile nature of the price of such digital assets and erratic market movements.***

In connection with the consummation of our recent offering of common shares and warrants, we acquired AVAX tokens for the establishment of our cryptocurrency treasury operations. Digital assets generally are highly volatile assets. In addition, digital assets do not pay interest or returns other than staking rewards and so the ability to generate a return on investment from the net proceeds of any financings will depend on whether there is appreciation in the value of digital assets following our purchases of digital assets with the net proceeds from such financings. Future fluctuations in digital asset trading prices may result in our converting digital assets into cash with a value substantially below what we paid for such digital assets. If investors perceive our share price as a proxy for AVAX tokens, the lack of a continuous redemption/creation arbitrage can cause persistent, material premiums or discounts to intrinsic value. While staking of AVAX tokens held by us can generate a return, there is no guarantee a market for staking of AVAX tokens will continue or expand or that the yield on such staking will remain at current levels.

***Our common stock may trade at a substantial premium or discount to the value of the AVAX tokens we hold, and our stock price may be more volatile than the price of AVAX tokens.***

The market price of our common stock reflects many factors that do not affect the spot price of AVAX tokens and may therefore diverge materially — positively or negatively — from the per-share value of our AVAX token holdings (net of cash, other assets and liabilities). These factors include, among others: our corporate-level expenses; taxes; the timing, size and pricing of equity or debt financings (including at-the-market offerings, equity line financings or convertible securities), equity awards and other sources of dilution; expectations about our future purchases or sales of AVAX tokens or staking activity; our liquidity and public float; differences in trading hours and market microstructure between our common stock and spot markets for AVAX tokens; changes in index inclusion, analyst coverage or investor sentiment toward us as an operating company; our corporate governance, financial reporting, and any actual or perceived operational, custody, technology or regulatory risks specific to us; and broader equity-market conditions independent of crypto-asset markets. As a result, our common stock may trade at a premium or discount to the value of our AVAX token holdings for extended periods, and may be more volatile than the price of tokens. Accordingly, investors could lose all or a substantial part of their investment even if the market price of AVAX tokens does not decline, and may AVAX not benefit commensurately from increases in the market price of AVAX tokens.

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This base prospectus and the documents incorporated herein by reference contain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this document and the materials accompanying this document are forward-looking statements. These statements are based on current expectations of future events. Frequently, but not always, forward-looking statements are identified by the use of the future tense and by words such as "believes," "expects," "anticipates," "intends," "will," "may," "could," "would," "projects," "continues," "estimates" or similar expressions. Forward-looking statements include statements regarding our expectations, hopes, beliefs or intentions regarding the future, including but not limited to statements regarding our market, strategy, competition, development plans (including acquisitions and expansion), financing, revenues, operations, and compliance with applicable laws. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These forward-looking statements speak only as of the date made and are subject to a number of known and unknown risks, uncertainties and assumptions, including the important factors incorporated by reference into this prospectus from our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act and in our other filings with the SEC, that may cause our actual results, performance or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements.

All forward-looking statements speak only as of the date of this prospectus. We disclaim any obligation to update or revise these statements, unless required by applicable law, and you should not rely on these forward-looking statements as predictions of future events. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this prospectus are reasonable, we can give no assurance that these plans, intentions or expectations will be achieved. These cautionary statements qualify all forward-looking statements attributable to us or persons acting on our behalf.

**USE OF PROCEEDS**

We are registering shares for selling stockholders and will receive no proceeds from the sale of shares registered hereunder.

**DESCRIPTION OF COMMON SHARES**

**General**

We are authorized to issue an unlimited number of common shares, at no par value per share. As of February 6, 2026, we had 91,748,303 common shares issued and outstanding.

Holders of the Company's common shares are entitled to one vote for each share on all matters submitted to a shareholder vote, except any meetings at which holders of another specified class or series of shares are entitled to vote separately. Holders of common shares do not have cumulative voting rights. At each annual general meeting number of directors to be elected for the ensuing year is set by shareholders pursuant to an ordinary resolution requiring approval by a majority of the votes cast at the meeting Once the number is set, that number of nominees receiving the greatest number of votes in favour of their election at the meeting will form the board of directors for the ensuing year. Holders of the Company's common shares representing 33.3% of the issued and outstanding common shares entitled to vote at the meeting, , represented in person or by proxy, are necessary to constitute a quorum at any meeting of shareholders. A vote by the holders of at least 2/3 of the votes cast at a general meeting is required to effectuate certain fundamental corporate changes such as liquidation, amalgamation or arrangement.

Holders of the Company's common shares are entitled to share in all dividends that the board of directors, in its discretion, declares from legally available funds. In the event of a liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain after payment of liabilities and after providing for each class of shares, if any, having preference over the common shares. The Company's common shares have no pre-emptive rights, no conversion rights and there are no redemption provisions applicable to the Company's common shares.

**Transfer Agent and Registrar**

The transfer agent and registrar for our common shares is Continental Stock Transfer & Trust Company, NY, NY.

**Listing**

Our common shares are currently traded on the Nasdaq Capital Market under the symbol "AVX."

**SELLING SECURITYHOLDERS**

**Selling Shareholders**

We are filing the prospectus supplement to permit the resale of up to 4,792,533 common shares issuable upon conversion of notes and exercise of warrants issued in the January 2, 2026 additional tranche of $7,000,000 of notes and warrants. Except for ownership of the Company's common shares and notes and warrants and as otherwise described in the documents incorporated by reference into this prospectus, the selling shareholders have not had any material relationship with us within the past three years.

The table below sets forth the name of the selling shareholders, the number and percentage of our common shares beneficially owned by the selling shareholders as of February 6, 2026, the number of common shares that may be offered by the selling shareholders under this prospectus, and the number and percentage of common shares beneficially owned by the selling shareholders assuming all of the common shares registered hereunder are sold. Applicable percentage ownership is based on 91,748,303 common shares issued and outstanding as of February 6, 2026, and beneficial ownership is determined in accordance with the rules of the SEC and includes voting or dispositive power with respect to AVX's common shares. Generally, a person "beneficially owns" a security if he, she or it possesses sole or shared voting or investment power over that security, including warrants and certain other derivative securities that are currently exercisable or will become exercisable within 60 days. Shares subject to warrants that are currently exercisable or exercisable within 60 days are considered outstanding and beneficially owned by the person holding such warrants for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. The information in the table below and the footnotes thereto regarding common shares to be beneficially owned after the offering assumes that the selling shareholders have exercised their warrants in full, despite the limitations on exercise in the warrants (including as described below), and further assumes that the selling shareholders sell all of the common shares being offered by them under this prospectus and do not acquire any common shares (other than the common shares issuable upon exercise of the selling shareholder warrants) prior to the offering.

Unless otherwise indicated, all information contained in the table below and the footnotes thereto is based upon information provided to AVX by the selling shareholders. The selling shareholders may have sold, transferred, otherwise disposed of or purchased, or may sell, transfer, or otherwise dispose of or purchase, at any time and from time to time, common shares in transactions exempt from the registration requirements of the Securities Act or in the open market after the date on which they provided the information set forth in the table below.

---

| | | | |
|:---|:---|:---|:---|
| **Selling Shareholder** | **Common Shares Beneficially Owned Before the Offering** | **Percent** | **Number of Common Shares to be Sold Pursuant to this Prospectus** |
| Anson Investments Master Fund LP | 1054356 | 1.1% | 1054356 |
| Anson East Master Fund LP | 3738175 | 4.07% | 3738175 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The shares, upon conversion
 of note and exercise of warrant, are directly held by Anson Investments Master
 Fund LP ("Anson Investments"). Anson Advisors Inc. and Anson Funds
 Management LP, the co-investment advisers of Anson Investments, hold voting and
 dispositive power over the Ordinary Shares held by Anson Investments. Tony Moore
 is the managing member of Anson Management GP LLC, which is the general partner
 of Anson Funds Management LP. Moez Kassam and Amin Nathoo are directors of Anson Advisors
 Inc. Mr. Moore Mr. Kassam and Mr. Nathoo each disclaim beneficial ownership over these securities.
 The principal business address of Anson Investments is Maples Corporate Services
 Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

&nbsp;&nbsp;&nbsp;&nbsp;(2) The shares, upon conversion of note
 and exercise of warrant, are directly held by Anson East Master Fund LP ("Anson East"). Anson Advisors
 Inc. and Anson Funds Management LP, the co-investment advisers of Anson East,
 hold voting and dispositive power over the Ordinary Shares held by Anson East.
 Tony Moore is the managing member of Anson Management GP LLC, which is the general
 partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo are directors
 of Anson Advisors Inc. Mr. Moore Mr. Kassam and Mr. Nathoo each disclaim beneficial
 ownership over these securities. The principal business address of Anson East is
 Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman
 Islands.

**PLAN OF DISTRIBUTION**

The selling shareholders may sell all or a portion of the common shares registered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If common shares are sold through underwriters or broker-dealers, the selling shareholders will be responsible for underwriting discounts or commissions or agent's commissions. The common shares registered hereby may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions, pursuant to one or more of the following methods:

● on
 any securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;

● in
 the over-the-counter market;

● in
 transactions otherwise than on these exchanges or systems or in the over-the-counter market;

● through
 the writing of options, whether such options are listed on an options exchange or otherwise

● ordinary
 brokerage transactions and transactions in which the broker-dealer solicits purchasers;

● block
 trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as
 principal to facilitate the transaction;

● purchases
 by a broker-dealer as principal and resale by the broker-dealer for its account;

● an
 exchange distribution in accordance with the rules of the applicable exchange;

● privately
 negotiated transactions;

● short
 sales effected after the effective date of the registration statement of which this prospectus is a part;

● sales
 pursuant to Rule 144;

● broker-dealers
 may agree with the selling shareholders to sell a specified number of such shares at a stipulated price per share;

● a
 combination of any such methods of sale; and

● any
 other method permitted pursuant to applicable law.

If the selling shareholders effect such transactions by selling common shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the selling shareholders or commissions from purchasers of the common shares for whom they may act as agent or to whom they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions involved). In connection with sales of the common shares or otherwise, the selling shareholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the common shares in the course of hedging positions they assume. After the registration statement of which this prospectus is a part is declared effective, the selling shareholders may also sell common shares short and deliver common shares covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The selling shareholders may also loan or pledge common shares to broker-dealers that in turn may sell such shares.

The selling shareholders may pledge or grant a security interest in some or all of the common shares or the selling shareholder warrants and, if it defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell the common shares if applicable, from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933, as amended, amending, if necessary, the list of selling shareholders to include the pledgees, transferees or other successors in interest as selling shareholders under this prospectus. The selling shareholders also may transfer and donate the common shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

The selling shareholders and any broker-dealer participating in the distribution of the common shares may be deemed to be "underwriters" within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the common shares is made, a prospectus supplement, if required, will be distributed, which will set forth the aggregate amount of common shares being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the selling shareholders and any discounts, commissions or concessions allowed or re-allowed or paid to broker-dealers.

Under the securities laws of some states, the common shares may be sold in such states only through registered or licensed brokers or dealers.

The selling shareholders may also sell the common shares under Rule 144 under the Securities Act, Rule 904 of Regulation S under the Securities Act, or any other exemption from registration under the Securities Act, in each case if available, rather than under this prospectus.

The selling shareholders and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the common shares by the selling shareholders and any other participating person. Regulation M may also restrict the ability of any person engaged in the distribution of the common shares to engage in market-making activities with respect to the common shares. All of the foregoing may affect the marketability of the common shares and the ability of any person or entity to engage in market-making activities with respect to the common shares.

We will pay all expenses of the registration of the common shares, including, without limitation, SEC filing fees; provided that the selling shareholders will pay all underwriting discounts and selling commissions, if any.

Once sold under the registration statement, of which this prospectus forms a part, the common shares will be freely tradable in the hands of persons other than our affiliates.

**LEGAL MATTERS**

The validity of the issuance of the securities offered by this prospectus will be passed upon for us by Farris LLP of Vancouver Canada. If certain legal matters in connection with an offering of the securities covered by this prospectus and a related prospectus supplement are passed upon by counsel for the underwriters, if any, of such offering, that counsel will be named in the related prospectus supplement for such offering.

**EXPERTS**

The consolidated balance sheets of AgriForce Growing Systems Ltd. as of December 31, 2024 and December 31, 2023, and the related consolidated statements of comprehensive loss, changes in shareholders' equity, and cash flows for the years then ended have been audited by Marcum LLP, as stated in its reports, which is incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

**WHERE YOU CAN FIND MORE INFORMATION**

We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website, www.avax-one.com under the heading "SEC Filings" in the "Investor Relations" section of our website. The information on our website is expressly not incorporated by reference into, and does not constitute a part of, this prospectus.

This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities offered hereby under the Securities Act of 1933, as amended. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules, in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and the securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings and the exhibits attached thereto. You should review the complete document to evaluate these statements.

**INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE**

This prospectus is part of a registration statement filed with the SEC. The SEC allows us to "incorporate by reference" into this prospectus the information that we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. The following documents are incorporated by reference and made a part of this prospectus:

● Annual Report on Form 10-K for the year ended December 31, 2024 filed on [April 7, 2025](https://www.sec.gov/Archives/edgar/data/1826397/000164117225002955/form10-k.htm) , as amended, and Quarterly Reports on Form 10-Q for the quarter ended March 31, 2025, filed on [May 15, 2025](https://www.sec.gov/Archives/edgar/data/1826397/000164117225010961/form10-q.htm) , for the quarter ended June 30, 2025, filed on [August 14, 2025](https://www.sec.gov/Archives/edgar/data/1826397/000164117225024019/form10-q.htm) and for the quarter ended on September 30, 2025, filed on [November 14, 2025](https://www.sec.gov/Archives/edgar/data/1826397/000149315225023464/form10-q.htm) ;

● Current Reports on Form 8-K (excluding any reports or portions thereof that are deemed to be furnished and not filed) filed on January [16](https://www.sec.gov/Archives/edgar/data/1826397/000149315225002585/form8-k.htm) , [24](https://www.sec.gov/Archives/edgar/data/1826397/000149315225003505/form8-k.htm) and [30](https://www.sec.gov/Archives/edgar/data/1826397/000149315225004221/form8-k.htm) , 2025, [March 10, 2025](https://www.sec.gov/Archives/edgar/data/1826397/000149315225009709/form8-k.htm) , April [7](https://www.sec.gov/Archives/edgar/data/1826397/000164117225002981/form8-ka.htm) and [25](https://www.sec.gov/Archives/edgar/data/1826397/000164117225006275/form8-k.htm) , 2025, May [1](https://www.sec.gov/Archives/edgar/data/1826397/000164117225008121/form8-k.htm) and [7](https://www.sec.gov/Archives/edgar/data/1826397/000164117225009082/form8-k.htm) , 2025, [June 6, 2025](https://www.sec.gov/Archives/edgar/data/1826397/000164117225014101/form8-k.htm) , [August 5, 2025](https://www.sec.gov/Archives/edgar/data/1826397/000164117225022238/form8-k.htm) , September [18](https://www.sec.gov/Archives/edgar/data/1826397/000149315225013992/form8-k.htm) and [22](https://www.sec.gov/Archives/edgar/data/1826397/000149315225014385/form8-k.htm) , 2025, October [23](https://www.sec.gov/Archives/edgar/data/1826397/000149315225019013/form8-k.htm) , and [27](https://www.sec.gov/Archives/edgar/data/1826397/000149315225019747/form8-k.htm) , 2025, November [6](https://www.sec.gov/Archives/edgar/data/1826397/000149315225021006/form8-k.htm) , [12](https://www.sec.gov/Archives/edgar/data/1826397/000149315225021948/form8-k.htm) , [13](https://www.sec.gov/Archives/edgar/data/1826397/000149315225022400/form8-k.htm) and [20](https://www.sec.gov/Archives/edgar/data/1826397/000149315225024469/form8-k.htm) , 2025 and January [26](https://www.sec.gov/Archives/edgar/data/1826397/000149315226003637/form8-k.htm) , [27](https://www.sec.gov/Archives/edgar/data/1826397/000149315226003716/form8-k.htm) and [28](https://www.sec.gov/Archives/edgar/data/1826397/000149315226004069/form8-k.htm) , 2026; and

● The description of our common shares contained in our registration statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1826397/000149315221015987/form-8a12b.htm) filed on July 2, 2021

● Our Definitive Proxy Statement on [Schedule 14A](https://www.sec.gov/Archives/edgar/data/1826397/000164117225008444/formdef14a.htm) and accompanying additional proxy materials filed with the SEC on May 5, 2025;

We also incorporate by reference all additional documents that we file with the Securities and Exchange Commission under the terms of Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act that are made after the date of the initial registration statement but prior to effectiveness of the registration statement and after the date of this prospectus but prior to the termination of the offering of the securities covered by this prospectus. We are not, however, incorporating, in each case, any documents or information that we are deemed to furnish and not file in accordance with Securities and Exchange Commission rules.

You may request, and we will provide you with, a copy of these filings, at no cost, by calling us at (604) 757-0952 or by writing to us at the address set forth on the cover of this registration statement.

**Up to 4,792,533 Common Shares**

**AVAX ONE TECHNOLOGY LTD.**

**Prospectus**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**, 2026** 

**PART II**

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 14. Other Expenses of Issuance and Distribution.**

The following table sets forth the costs and expenses payable by the Registrant in connection with this offering, other than underwriting commissions and discounts, all of which are estimated except for the SEC registration fee.

---

| | |
|:---|:---|
| **Item** | **Amount** |
| SEC registration fee | $481.16 |
| Printing and engraving expenses | \* |
| Legal fees and expenses | \* |
| Accounting fees and expenses | \* |
| Transfer agent and registrar's fees and expenses | \* |
| Miscellaneous expenses | \* |
| Total | \* |

---

\* These expenses are not presently known and cannot be estimated at this time as they are based upon the amount and type of security being offered, as well as the number of offerings. The aggregate amount of these expenses will be reflected in the applicable prospectus supplement.

**Item 15. Indemnification of Directors and Officers.**

Our bylaws, as amended, provide to the fullest extent permitted by British Columbia law, that our directors or officers shall not be personally liable to us or our shareholders for damages arising from the performance of such director's or officer's duties. The effect of this provision of our bylaws, as amended, is to eliminate our right and our shareholders' rights (through shareholders' derivative suits on behalf of our Company) to recover damages against a director or officer arising from the performance of such director's or officer's duties, except under certain situations defined by statute. We believe that the indemnification provisions in our bylaws, as amended, are necessary to attract and retain qualified persons as directors and officers.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**Item 16. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description of Document** |
| 4.1 | [Articles of Incorporation and Bylaws (incorporated by reference to the Company's Registration Statement on Form S-1 filed with the SEC on December 16, 2020).](https://www.sec.gov/Archives/edgar/data/1826397/000149315220023737/ex3-1.htm) |
| 5.1 | Legal Opinion\* |
| 23.1 | [Consent of Marcum LLP.\*\*](ex23-1.htm) |
| 23.2 | Consent of Legal Counsel (contained in Exhibit 5.1)\* |
| 24.1 | [Power of Attorney (included on the signature pages of this registration statement)](#POA) |
| 107 | [Filing Fee Table\*\*](ex107.htm) |

---

\* To be filed by amendment or by a Current Report on Form 8-K and incorporated by reference herein. <br>\*\* Filed herewith.

**Item 17. Undertakings**

(a) The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933, as amended (the "Securities Act");

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

*provided, however*, Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

(i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; *provided, however,* that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

(5) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b) The undersigned registrant hereby undertakes that for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

(d) The registrant hereby undertakes that, for purposes of determining any liability under the Securities Act:

(1) the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and

(2) each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement or Amendment thereto to be signed on its behalf by the undersigned, thereunto duly authorized, in Vancouver, BC, Canada, on February 9, 2026.

---

| | |
|:---|:---|
| **AVAX ONE TECHNOLOGY LTD.** | **AVAX ONE TECHNOLOGY LTD.** |
| By: | */s/ Jolie Kahn* |
| Name: | Jolie Kahn |
| Title: | Chief Executive Officer |
| By: | */s/ Chris Polimeni* |
| Name: | Chris Polimeni |
| Title: | Chief Financial Officer |

---

Each person whose signature appears below hereby constitutes and appoints Jolie Kahn and Chris Polimeni and each of them, individually, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead in any and all capacities, in connection with this registration statement, including to sign in the name and on behalf of the undersigned, this registration statement and any and all amendments thereto, including post-effective amendments and registrations filed pursuant to Rule 462 under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto such attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or his or her substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Jolie Kahn* | Chief Executive Officer (Principal Executive Officer) | February 9, 2026 |
| Jolie Kahn |  |  |
| */s/ Chris Polimeni* | Chief Financial Officer (Principal Financial and Accounting Officer) | February 9, 2026 |
| Chris Polimeni |  |  |
| */s/ Matt Zhang* | Director | February 9, 2026 |
| Matt Zhang |  |  |
| */s/ Young Cho* | Director | February 9, 2026 |
| Young Cho |  |  |
| */s/ Amy Griffith* | Director | February 9, 2026 |
| Amy Griffith |  |  |
| */s/ Dan Mendes* | Director | February 9, 2026 |
| Dan Mendes |  |  |
| */s/ Xiao Xiao Zhu* | Director | February 9, 2026 |
| Xiao Xiao Zhu |  |  |

---

## Exhibit 23.1

**Exhibit 23.1**

**<u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>**

We consent to the incorporation by reference in this Registration Statement on Form S-3 of our report dated April 7, 2025 with respect to the financial statements of AVAX One Technology Ltd. (formerly known as AgriFORCE Growing Systems Ltd.) for the years ended December 31, 2024 and 2023 included in the Annual Report on Form 10-K. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

/s/ Marcum LLP

Costa Mesa, CA

February 9, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**CALCULATION OF FILING FEE TABLES**

Form S-3

**(Form Type)**

AVAX One Technology Ltd.

**(Exact Name of Registrant as Specified in its Charter)**

Table 1: Newly Registered Securities

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Security<br> Type | Security Class Title | Fee<br> Calculation<br> or Carry<br> Forward<br> Rule | Amount<br> Registered | Proposed<br> Maximum<br> Offering<br> Price Per<br> Share | Maximum<br> Aggregate<br> Offering<br> Price |  | Fee Rate | Amount of<br> Registration<br> Fee |
| Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities |
| Fees to be<br> Paid | Equity | Common Shares, no par value per share | 457(o) | (1) 4792533 | (1)0.727 | 3484171 | (1) | $0.0001381 | 481.16 |
| Fees<br> Previously<br> Paid |  |  |  |  |  |  |  |  |  |
| Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities |
| Carry<br> Forward<br> Securities |  |  |  |  |  |  |  |  |  |
|  | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | $3484171 |  | $0.0001381 | $481.16 |
|  | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid |  |  |  |  |
|  | Total Fees Offsets | Total Fees Offsets | Total Fees Offsets | Total Fees Offsets | Total Fees Offsets |  |  |  |  |
|  | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  | $481.16 |

---

(1) Fee
 based on per share closing price on February 4, 2026. The securities registered hereunder also include such indeterminate number
 of each class of identified securities as may be issued upon conversion, exercise, redemption or exchange of any other securities
 that provide for such conversion into, exercise for, redemption of or exchange into such securities. Separate consideration may or
 may not be received for securities that are issuable on exercise, conversion, redemption or exchange of other securities. In addition,
 pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the common shares and preferred
 shares being registered hereunder include such indeterminate number of additional shares as may be issuable with respect to the shares
 being registered hereunder as a result of share splits, share dividends, distributions or similar transactions. The proposed offering
 price per security will be determined, from time to time, by the registrant in connection with the sale of the securities under this
 Registration Statement.